 |
26 Diseases |  |
6 Trials |
|
6 Trials |  |
4342 News |  |
| «12...2223242526272829303132...5051» |
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Irish Cardiac Society: Residual risk in cardiac rehab: can we REDUCE-IT MORE? Eligibility for icosapent ethyl in patients attending cardiac rehabilitation #reduceit .@DLBHATTMD .@omega360 https://t.co/xNVKmBXy1X (Twitter) - Oct 3, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
PCSK9i and Vascepa. (Twitter) - Oct 2, 2020
- || ezetimibe / Generic mfg., Vascepa (icosapent ethyl) / Amarin, HLS Therap
Review, Journal: Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. (Pubmed Central) - Oct 2, 2020
In addition, a recent trial of icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, addresses residual risk in patients with elevated triglycerides already treated with statins. The use of both sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes reduces cardiovascular events independently of glucose lowering.
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Vascepa (Twitter) - Oct 1, 2020
- || Clinical, Review, Journal: Dyslipidemia Management in Adults With Diabetes. (Pubmed Central) - Oct 1, 2020
High-dose icosapent ethyl is another worthwhile add-on treatment, especially in statin-treated patients with diabetes in whom triglyceride levels remain elevated...Several existing and newer drug treatments reduce ASCVD risk through LDL cholesterol and/or triglyceride reduction in patients with diabetes. Novel approaches using antisense oligonucleotides and monoclonal antibodies may provide potential future therapies for diabetic dyslipidemia.
- || icosapent ethyl / Generic mfg.
Review, Journal: Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. (Pubmed Central) - Sep 30, 2020
Novel approaches using antisense oligonucleotides and monoclonal antibodies may provide potential future therapies for diabetic dyslipidemia. Consumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
FDA event, Journal, Head-to-Head: Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M and spike protein: Drug repurposing approach. (Pubmed Central) - Sep 30, 2020
Therefore, cilostazol is a promising FDA drug against COVID-19 by inhibiting both M and S protein. The insights gained in this study may be useful for quick approach against COVID-19 in the future.
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Journal: Omega-3 fatty acid therapy for cardiovascular disease: justified or not? (Pubmed Central) - Sep 26, 2020
The insights gained in this study may be useful for quick approach against COVID-19 in the future. At present, the best available evidence for a role of omega-3 fatty acids in ASCVD risk reduction is for 4 g/day of IPE, as an adjunct to statin therapy, for patients with ASCVD or diabetes mellitus and elevated triglycerides.
- || Nexletol (bempedoic acid) / Esperion Therap, Otsuka, inclisiran (ALN-PCSsc) / Alnylam, Novartis, Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, Journal: 2019 clinical trials in lipid lowering. (Pubmed Central) - Sep 26, 2020
As therapies for ASCVD prevention continue to emerge, clinicians will need to identify the appropriate treatment for individuals based on their estimated risk and risk-enhancing factors. When statin therapy is either not sufficient or patients do not tolerate adequate statin therapy, relying on newer therapies, such as PCSK9-inhibitors, inclisiran, bempedoic acid and icosapent ethyl, will be critical to maximize risk factor profiles to reduce adverse outcomes.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
What if we go further down and add Icosapent Ethyl ? (Twitter) - Sep 25, 2020
- | icosapent ethyl / Generic mfg.
Enrollment open: IPE-PREVENTION: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk (clinicaltrials.gov) - Sep 24, 2020
P4, N=70, Recruiting, Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
When statin therapy is either not sufficient or patients do not tolerate adequate statin therapy, relying on newer therapies, such as PCSK9-inhibitors, inclisiran, bempedoic acid and icosapent ethyl, will be critical to maximize risk factor profiles to reduce adverse outcomes. Not yet recruiting --> Recruiting
- ||||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Can Icosapent Ethyl Improve Bone Mineral Health with Metabolic Syndrome? @UM_Cardiology @nationallipid @ASPCardio @Amarincorp @UMmedschool @clinthe @AARPresearch (Twitter) - Sep 24, 2020
- | icosapent ethyl / Generic mfg.
New P4 trial: IPE-PREVENTION: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk (clinicaltrials.gov) - Sep 23, 2020
P4, N=70, Not yet recruiting, Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Just prescribed icosapent ethyl for the first time! Thanks to my #ACCFIT @KrittanawongMD for suggesting it! #ReduceIT @CBallantyneMD @virani_md @vijay_nambi @jia_xiaoming @AlizaHussainMD @BCMHeart @mahrifai @DLBHATTMD #ACCEarlyCareer #CardioTwitter #MedEd (Twitter) - Sep 23, 2020
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT (OnDemand) - Sep 22, 2020 - Abstract #AHA2020AHA_4585;
Not yet recruiting --> Recruiting In all subgroups, IPE at a cost of $4.16/day was shown to be cost-effective at a willingness-to-pay threshold of $50,000 per QALY and was a dominant treatment strategy in most subgroups.
- | icosapent ethyl / Generic mfg.
Trial completion: EVAPORATE: Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy (clinicaltrials.gov) - Sep 22, 2020
P4, N=80, Completed, Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
In all subgroups, IPE at a cost of $4.16/day was shown to be cost-effective at a willingness-to-pay threshold of $50,000 per QALY and was a dominant treatment strategy in most subgroups. Active, not recruiting --> Completed
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Congrats @ThomasMDas (#OslerPride) & @hopkinsheart fellow Dr. Karan Kapoor on this summary of the #EVAPORATE trial. "Seeing is Believing". #EPA #IcosapentEthyl #plaque reduction. With @rblument1 https://t.co/UaL73Zqtf4 (Twitter) - Sep 22, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Read the latest #review in Future #Cardiology by @DLBHATTMD and co-authors on the impact of expanded #FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction for free here: https://t.co/VYicM6cONn #cardiotwitter #diabetes (Twitter) - Sep 22, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction | Future Cardiology https://t.co/qDyhTysuQ2 #cardiotwitter #Cardiology #diabetes @webmd11 (Twitter) - Sep 22, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal, HEOR: The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective. (Pubmed Central) - Sep 21, 2020
Patients with established CVD in whom level of triglycerides is high would benefit from the treatment using icosapent ethyl, however, it is not a cost-effective from an Australian healthcare system perspective. The government may consider subsidising this medication given the clinical need but at a discounted acquisition cost.
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: .@VietHeartPA , .@DLBHATTMD I know you're likely aware of this one already via Michael Miller et al but just in case. 😎 Effect of Icosapent Ethyl on Gynoid Fat and Bone Mineral Health in the Metabolic Syndrome: a Preliminary Report https://t.co/BUY6SwWEzG (Twitter) - Sep 21, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Will Icosapent Ethyl have a similar effect? Does it have an intravenous preparation? @DLBHATTMD (Twitter) - Sep 19, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Review, Journal: Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk. (Pubmed Central) - Sep 18, 2020
Based on the REDUCE-IT trial, the FDA granted IPE an indication for ASCVD risk reduction, making it the first O3FA product to receive such an indication. IPE is a cost-effective approach to reducing residual cardiovascular risk in statin-treated, high risk patients.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Review, Journal: Targeting Hypertriglyceridemia to Mitigate Cardiovascular Risk: A Review. (Pubmed Central) - Sep 18, 2020
The REDUCE-IT trial demonstrated that addition of purified prescription eicosapentaenoic acid (icosapent ethyl) 4 g/day in high-risk patients with triglyceride levels 135-499 mg/dL and optimized statin treatment significantly reduced cardiovascular events versus placebo (hazard ratio 0.75; 95% confidence interval 0.68-0.83; P<0.001). Benefit was seen regardless of baseline and on-treatment triglyceride levels, suggesting that other effects of eicosapentaenoic acid besides triglyceride reduction may have played a role.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_3404;
Icosapent ethyl significantly reduced multiple types of ischemic events, both by independent, blinded adjudication as well as by investigator-reported assessment. These results underscore the robustness of the benefits of icosapent ethyl seen in REDUCE-IT.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Icosapent Ethyl Therapy for Patients With an Established Cardiovascular Disease Provides Significantly More Value for Money Than When Prescribed as Primary Prevention (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2999;
The CNT for patients receiving the drug for primary prevention of MACE was four-fold higher than when provided as secondary prevention. Our findings suggest that icosapent ethyl therapy for patients with an established CVD provides significantly more value for money.
- Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
[VIRTUAL] External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2948;
In patients with T2D and established ASCVD treated in EMPA-REG OUTCOME, about one-quarter of patients would qualify for IPE according to the REDUCE-IT inclusion criteria. Empagliflozin consistently reduced CV outcomes and mortality in this sub-group, suggesting that IPE and SGLT2 inhibition may be complementary.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Achieved Eicosapentaenoic Acid (EPA) Levels Predicts Regression of Coronary Plaque Volumes by Coronary Computed Tomography Angiography (CCTA) in the EVAPORATE Trial (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2691;
In REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), icosapent ethyl (IPE) added to statins reduced initial and total CV events by 25% and 30%, but the mechanisms of benefit are unclear...ConclusionsHigher serum EPA levels predict regression of prognostically relevant coronary plaque volumes, TNCP, and TP on CCTA. This provides important mechanistic correlation to the CV benefits of IPE.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Effect of Icosapent Ethyl on Changes in Coronary Plaque Characteristics at 9 Months in Patients With Elevated Triglycerides on Statin Therapy: Insights From EVAPORATE (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_2587;
Operating points when used as a per-patient measure of response are presented in Figure 1. Conclusions This study demonstrated that IPE, when added to statin therapy, is associated with reduction in vulnerable plaque, moving patients to a more stable plaque phenotype.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Omega-3 Ethyl Esters and Atrial Fibrillation or Flutter in Patients With Coronary Artery Disease: Results From a Randomized Trial (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_956;
EPA/DHA did not increase the incidence of Afib or flutter in patients with established CAD. Further studies are warranted to better understand the effects of omega-3 ethyl esters on the cardiac conduction system.
- Vascepa (icosapent ethyl) / Amarin, HLS Therap
[VIRTUAL] Contrasting Effects of Phospholipid Linked Eicosapentaenoic Acid and Arachidonic Acid on Membrane Structure and Stability (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_239;
PL-EPA causes membrane stability in a manner that is disrupted by the presence of PL-AA. The contrasting effects of PL-EPA and PL-AA on membrane structure may contribute to differences in biological activity.
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery: Current Opinion in Cardiology https://t.co/WRqIJhacku #cardiotwitter #cardiology #surgerytwitter #surgery (Twitter) - Sep 15, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Vascepa is the first and only anti-lipid med to cause plaque regression in coronaries. Show me a study with statin causing any plaque regression in RCT manner. (Twitter) - Sep 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Episode 3.11 is out now! Expert speakers, lockdown policy, Norman Wang and affirmative action & COVID-19 and hearts (and Vascepa!) with @ProfDFrancis Back us on Patreon! https://t.co/FTUdi7ZRkn Sign up for our mailing list: https://t.co/J5BrgeGX13 https://t.co/e9Hkidjisi (Twitter) - Sep 12, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Final EVAPORATE Results for Vascepa Raise Eyebrows https://t.co/CCmj0XAhnj via @medscape (Twitter) - Sep 11, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Oh yeah. The $AMRN Vascepa investor realtor guy. Seriously don’t miss this advert. I think the idea is to whistle this jingle all the way to the bank. (𝑺𝒆𝒓𝒊𝒐𝒖𝒔𝒍𝒚 𝒅𝒐𝒏’𝒕 𝒎𝒊𝒔𝒔 𝒕𝒉𝒊𝒔 𝒂𝒅𝒗𝒆𝒓𝒕) (Twitter) - Sep 11, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Amarin's Vascepa may prove to be an effective tool in the fight against covid-19, due to its remarkable anti-inflammatory effects. As a bonus, it reduces heart attacks & reduces arterial plague! @DLBHATTMD @BudoffMd https://t.co/tZuXKKvOlr (Twitter) - Sep 8, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
According to https://t.co/mLmjd3vvCm there are three (3) trials of Vascepa and Covid19. My guess is it’s a valiant attempt to get some of that government money. (Twitter) - Sep 8, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: And not moved on to the 99th Century methods favoured by myself and the VASCEPA trial, where we can't be doing with placebo's and all that jazz. We keep it simple, natural and wholesome, down our way. (Twitter) - Sep 8, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Also had a position, though not a large one. What gets my goat is to this day there remains skepticism of Vascepa. Skepticism can prove non-obviousness. But the IP is invalidated as obvious because the judge says skepticism was wrong. Does the judge only want to patent shams? (Twitter) - Sep 8, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
VASCEPA for COVID. Hat tip to @Charliexart for this exciting crossover news. https://t.co/JXCViJm3AR (Twitter) - Sep 8, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Oh please, I'm proud of it. Its called learning and due diligence. You are the guy who slanders and ambushes legitimate researchers on Twitter If 100% of your posts were Amarin -- icosapent ethyl -- we'd be better off. You might know enough about the topic, instead of data (Twitter) - Sep 7, 2020
- ||| Keyzilen (esketamine) / Auris Medical, Vascepa (icosapent ethyl) / Amarin, HLS Therap
Odd only from parochial perspective. Why shouldn't a Realtor be interested? Realtors are smarter, more curious than the ones you have met apparently. I've been in for a decade. When the icosapent ethyl failed as AMR101 on alzheimer, it was clear that it had cardio potential (Twitter) - Sep 7, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
We revisit Vascepa on this podcast! (Twitter) - Sep 7, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Actually links beautifully to your previous episode as the troll was a Vascepa investor 😂😂 (Twitter) - Sep 7, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN Only an attention starved Jabroni ambushes a respected researcher on twitter. Passive aggressive. No balls. It's really that simple. #cardiotwitter #clown Icosapent Ethyl @ProfDFrancis @budoffmd https://t.co/8A96l9851r (Twitter) - Sep 7, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN Only an attention starved Jabroni ambushes a respected researcher on twitter. Passive aggressive. No balls. It's really that simple. #cardiotwitter #clown Icosapent Ethyl @ProfDFrancis @budoffmd https://t.co/8A96l9851r (Twitter) - Sep 7, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: It was a twitter ambush. Francis is not a serious man. Childish. If he was, he would have contact Budoff directly first. A #clown. $AMRN #evaporate Icosapent Ethyl #cardiotwitter (Twitter) - Sep 7, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Interview: In a recent interview, @DLBHATTMD offers perspective on REDUCE-IT analyses and icosapent ethyl (Vascepa) data presented at ESC Congress 2020. https://t.co/Sk2aR7XJzl (Twitter) - Sep 6, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Even if you don't think you are interested in drug patent disputes, you will want to listen to @JonathanDarrow explain the Vascepa litigation. It is fascinating and he breaks it down so well. (Twitter) - Sep 5, 2020